TEMPUS AI INC

Company Overview

Tempus AI Inc. is a healthcare-focused health information services company that combines large-scale genomics testing, oncology diagnostics, and data & services products for life sciences and provider customers. Recent quarters show rapid revenue expansion driven by the Feb 2025 Ambry acquisition (added ~128k hereditary tests in Q2 and material cash consideration) and higher average oncology reimbursement (including Medicare), while Data & Services growth benefited from Insights deliveries and the Pathos/Foundation model arrangement. The company remains investment‑heavy — continuing to prioritize R&D, technology and commercial scale — and is operating with improving margins but ongoing operating losses, significant amortization and interest expense, $188.1M of cash at 6/30/25, and a $2.3B accumulated deficit. Management cites payer reimbursement variability, integration and financing risks, and potential future capital needs as key near‑term drivers.

Executive Compensation Practices

Given Tempus’s business model and the filing detail, executive pay is likely tied heavily to growth and transaction-driven milestones — revenue and genomics test volumes, average reimbursement per oncology test, adjusted EBITDA or adjusted operating metrics, and successful integration of acquisitions (e.g., Ambry). The company historically uses substantial stock‑based compensation (noted large year‑ago SBC charges that distorted 2024 comparatives), which suggests equity grants, RSUs/options and milestone/retention awards are material components of total pay to conserve cash and align executives with long‑term value creation. Recent financings (term loans, revolving facility and convertible notes) and dilution risk from deal-related equity or convertible instruments make equity compensation valuation sensitive to capital structure changes; boards commonly layer performance vesting tied to commercial milestones, R&D progress and cash‑flow/covenant preservation in this context.

Insider Trading Considerations

Insider trading patterns at Tempus will likely cluster around material events: acquisition announcements and integration updates (Ambry, Deep 6), financing transactions (convertible notes, capped calls), quarterly results (revenue, reimbursement trends, adjusted EBITDA), and large commercial agreements (Pathos/AstraZeneca). Watch Form 4 filings for option exercises and sales — equity‑heavy compensation and concentrated insider holdings can produce opportunistic exercises/sales for diversification or tax funding, while insider purchases may be a stronger signal given cash‑runway and covenant concerns. Regulatory controls (Section 16 reporting, blackout windows, Rule 10b5‑1 plans) and the sensitivity of nonpublic payer, reimbursement and clinical data (privacy/regulatory restrictions) increase the likelihood of tightened trading windows and deliberate, pre‑planned trading around material information.